trending Market Intelligence /marketintelligence/en/news-insights/trending/_yrrx_1j_ul5tuolxlfbyw2 content esgSubNav
In This List

US judge reverses $2.54B hepatitis C drug patent verdict against Gilead

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


US judge reverses $2.54B hepatitis C drug patent verdict against Gilead

A federal judge in Delaware ruled that Gilead Sciences Inc. no longer has to pay Merck & Co. Inc. a record $2.54 billion in damages under a previous patent infringement verdict, Reuters reported.

In December 2016, a federal jury in a U.S. District Court in Delaware ordered Gilead to pay the amount after deciding that its blockbuster hepatitis C therapies Sovaldi and Harvoni infringed a Merck patent. The jurors found the patent, which covers hepatitis C treatments, valid.

U.S. District Judge Leonard Stark reversed the verdict Feb. 16, ruling Merck's patent invalid because it failed to meet a rule requiring the company to disclose how to make the drug the patent covered without undue experimentation.

Merck plans to appeal the verdict, Reuters reported, citing a statement by the New Jersey-based drugmaker. Merck acquired the patent when it bought Idenix Pharmaceuticals Inc. in 2014.